Mark Kavanagh, a 27-year-old man from Rathfarnham, Dublin, has settled a High Court action for €5 million against Tallaght University Hospital and the Health Service Executive (HSE).
The case centered on allegations that his mother was not adequately informed of the risks associated with taking the epilepsy medication sodium valproate during pregnancy.
The settlement was reached after mediation and is without an admission of liability, The Irish Times reported. Kavanagh, who was born on September 3, 1998, lives with spina bifida and seizures, injuries he claims resulted from in utero exposure to the drug, marketed under the brand name Epilim.
Sodium valproate is an anticonvulsant medication used to manage seizures and bipolar disorder. Its mechanism of action involves increasing the concentration of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, within the brain. While effective for seizure control, the drug is a known teratogen, meaning it can cause malformations in a developing fetus.
Clinical data indicates that prenatal exposure to valproate is associated with a significantly increased risk of neural tube defects, such as spina bifida, as well as neurodevelopmental disorders. Regulatory bodies, including the European Medicines Agency (EMA) and the Health Products Regulatory Authority (HPRA) in Ireland, have implemented strict pregnancy prevention programs to ensure patients are fully informed of these risks before initiating treatment.
- Teratogenicity: Sodium valproate can interfere with normal fetal development, particularly the formation of the spinal cord and brain.
- Informed Consent: Physicians are required to discuss the potential for birth defects with patients of childbearing potential and provide information on safer alternative anticonvulsants when possible.
- Ongoing Monitoring: Patients currently prescribed valproate should never stop their medication abruptly, as this can trigger life-threatening seizures; instead, they should consult their neurologist to evaluate their treatment plan.
In court, counsel for Kavanagh argued that his mother was diagnosed with epilepsy in the early 1990s and was prescribed Epilim both before and during her pregnancy.
The legal action contended that there was a failure to discuss her intentions to conceive or to advise on alternative medications that might carry a lower risk profile. Liability was denied by the defendants, who maintained that the clinical management provided was consistent with the general neurological practice of that era.
Judge Tony O’Connor approved the settlement, noting that Kavanagh expressed deep appreciation for his mother’s care throughout his life. The case highlights the evolution of clinical communication regarding medication risks and the standard of care expected in prenatal neurological management.
| Clinical Factor | Valproate Risk Profile |
|---|---|
| Primary Use | Epilepsy and Bipolar Disorder |
| Fetal Risk (Spina Bifida) | Estimated ~1% (Baseline population risk <0.1%) |
| Regulatory Status | Restricted use for females of childbearing potential |
| Action Required | Mandatory pregnancy prevention counseling |
Sodium valproate is generally contraindicated for women who are pregnant or planning to become pregnant unless no other effective treatment is available. Patients currently taking this medication should consult their GP or neurologist immediately if they are considering pregnancy or if they have concerns about their current dosage.
Seek urgent medical attention if you experience signs of an allergic reaction or if a patient on this medication shows sudden changes in mood, cognitive function, or seizure frequency. Never adjust or discontinue anti-epileptic therapy without direct supervision from a medical professional, as the risk of uncontrolled status epilepticus—a prolonged, continuous seizure—outweighs the risks of continued treatment in many clinical scenarios.
